STRENSIQ (asfotase alfa)
METABOLIC DISEASE ENZYME REPLACEMENT - HYPOPHOSPHATASIA · CHILDHOOD HYPOPHOSPHATASIA ·+1
ALEXION PHARMAC
Drug class
Metabolic Disease Enzyme Replacement - Hypophosphatasia
Metabolic disease enzyme replacement therapies for hypophosphatasia represent a specialized pharmacologic category of recombinant enzymes indicated for patients with hypophosphatasia. Read more about Metabolic Disease Enzyme Replacement - Hypophosphatasia
1 drugs in this class 1 manufacturers
Drugs in Metabolic Disease Enzyme Replacement - Hypophosphatasia
Filter & compare in the drug finder →
Opens the drug finder with Metabolic Disease Enzyme Replacement - Hypophosphatasia preselected. Add indication or manufacturer filters there.
Metabolic disease enzyme replacement therapies for hypophosphatasia represent a specialized pharmacologic category of recombinant enzymes indicated for patients with hypophosphatasia.
These agents—most notably bone-targeted tissue-nonspecific alkaline phosphatase fusion proteins such as asfotase alfa—work by directly replacing the deficient endogenous alkaline phosphatase enzyme.
By hydrolyzing extracellular inorganic pyrophosphate, an inhibitor of bone mineralization, they restore physiological calcium and phosphate deposition into hydroxyapatite crystals.
Clinically, this class is utilized to treat perinatal-, infantile-, and juvenile-onset hypophosphatasia to improve skeletal mineralization, reduce rickets and fracture risk, and prevent systemic metabolic complications.
-
fda.gov
Metabolic disease enzyme replacement therapies for hypophosphatasia represent a specialized pharmacologic category of recombinant enzymes indicated for patients with hypophosphatasia These agents—most notably bone-targeted tissue-nonspecific alkaline phosphatase fusion proteins such as asfotase alfa—work by directly replacing the deficient endogenous alkaline phosphatase enzyme Clinically, this class is utilized to treat perinatal-, infantile-, and juvenile-onset hypophosphatasia to improve skel...
-
nih.gov
Metabolic disease enzyme replacement therapies for hypophosphatasia represent a specialized pharmacologic category of recombinant enzymes indicated for patients with hypophosphatasia
-
nih.gov
These agents—most notably bone-targeted tissue-nonspecific alkaline phosphatase fusion proteins such as asfotase alfa—work by directly replacing the deficient endogenous alkaline phosphatase enzyme
-
formularynavigator.com
By hydrolyzing extracellular inorganic pyrophosphate, an inhibitor of bone mineralization, they restore physiological calcium and phosphate deposition into hydroxyapatite crystals Clinically, this class is utilized to treat perinatal-, infantile-, and juvenile-onset hypophosphatasia to improve skeletal mineralization, reduce rickets and fracture risk, and prevent systemic metabolic complications
-
fda.gov
By hydrolyzing extracellular inorganic pyrophosphate, an inhibitor of bone mineralization, they restore physiological calcium and phosphate deposition into hydroxyapatite crystals
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.